Evidence map›Paper›PMID 28208158›Full record

ArticleBritish journal of cancer2017

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.

Shana J Kim, Barry Rosen, Isabel Fan, Anna Ivanova, John R McLaughlin, Harvey Risch, Steven A Narod, Joanne Kotsopoulos

Abstract read
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Cellular origins of mucinous ovarian carcinoma.The Journal of pathology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shana J KimWomen's College Research Institute, Women's College Hospital, 76 Grenville, Toronto, ON, Canada.
Barry RosenPrincess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON, Canada.
Isabel FanSamuel Lunenfeld Research Institute, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, 600 University Avenue, Toronto, ON, Canada.
Anna IvanovaWomen's College Research Institute, Women's College Hospital, 76 Grenville, Toronto, ON, Canada.
John R McLaughlinSamuel Lunenfeld Research Institute, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, 600 University Avenue, Toronto, ON, Canada.
Harvey RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT, USA.
Steven A NarodWomen's College Research Institute, Women's College Hospital, 76 Grenville, Toronto, ON, Canada.
Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, 76 Grenville, Toronto, ON, Canada.

Funding

RISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSR01CA063678 · NCI · UNIVERSITY OF TORONTO · PI NAROD, STEVEN A · 1994 to 1999
–
GENETIC/EPIDEMIOLOGY STUDY OF EPITHELIAL OVARIAN TUMORSR01CA063682 · NCI · YALE UNIVERSITY · PI RISCH, HARVEY A · 1994 to 1998
–
NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682
6 · The paper itself

Abstract

backgroundVarious epidemiologic factors have been shown to influence the risk of ovarian cancer development. Given the high fatality associated with this disease, it is of interest to evaluate the association of prediagnostic hormonal, reproductive, and lifestyle exposures with ovarian cancer-specific survival.

methodsWe included 1421 patients with invasive epithelial ovarian cancer diagnosed in Ontario, Canada. Clinical information was obtained from medical records and prediagnostic exposure information was collected by telephone interview. Survival status was determined by linkage to the Ontario Cancer Registry. Proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for ovarian cancer-specific mortality associated with each exposure. Analyses were stratified by histologic subtype to further investigate the associations of risk factors on ovarian cancer-specific mortality.

resultsAfter a mean follow-up of 9.48 years (range 0.59-20.32 years), 655 (46%) women had died of ovarian cancer. Parity (ever) was associated with a significant 29% decreased mortality risk compared with nulliparity (HR=0.71; 95% CI 0.54-0.93; P=0.01). There was a borderline significant association between ever use of oestrogen-containing hormone replacement therapy (HRT) and mortality (HR=0.79; 95% CI 0.62-1.01; P=0.06). A history of cigarette smoking was associated with a significant 25% increased risk of death compared with never smoking (HR=1.25; 95% CI 1.01-1.54; P=0.04). Women with a greater cumulative number of ovulatory cycles had a significantly decreased risk of ovarian cancer-specific death (HR=0.63; 95% CI 0.43-0.94; P=0.02). Increasing BMI (kg m

conclusionsParity, ovulatory cycles, smoking, and BMI may affect survival following the diagnosis of ovarian cancer. Whether or not oestrogen-containing HRT use is beneficial for survival requires further evaluation.

Indexed as

Adenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedCanadaCystadenocarcinoma, SerousEndometrial NeoplasmsEpidemiologic FactorsFemaleFollow-Up StudiesHormone Replacement TherapyHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian Neoplasms

Identifiers

PMID28208158
PMCPMC5379147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.